<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01201161</url>
  </required_header>
  <id_info>
    <org_study_id>RANITRA</org_study_id>
    <nct_id>NCT01201161</nct_id>
  </id_info>
  <brief_title>Ranibizumab for Diabetic Traction Retinal Detachment</brief_title>
  <acronym>RANITRA</acronym>
  <official_title>The Effect of Intravitreous Ranibizumab on Intra-Operative Bleeding During Pars Plana Vitrectomy for Diabetic Traction Retinal Detachment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the effect of ranibizumab in reducing intraoperative
      vitreous haemorrhage during pars plana vitrectomy, thus facilitating surgery and improving
      its anatomical and functional results in patients with advanced proliferative diabetic
      retinopathy and traction retinal detachment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amount of intraoperative intra-ocular bleeding</measure>
    <time_frame>one week</time_frame>
    <description>amount of intra-ocular bleeding that occurred during pars plana vitrectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity</measure>
    <time_frame>12 weeks</time_frame>
    <description>ETDRS best corrected visual acuity at 12 weeks after pars plana vitrectomy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retinal Detachment</condition>
  <arm_group>
    <arm_group_label>RANI/PPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative intravitreal ranibizumab and pars plana vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham injection and pars plana vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy</description>
    <arm_group_label>RANI/PPV</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Simulation of intravitreal injection one week before pars plana vitrectomy</description>
    <arm_group_label>PPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macular traction retinal detachment lasting three months or less secondary to diabetic
             retinopathy.

        Exclusion Criteria:

          -  Massive vitreous hemorrhage preventing from detailed posterior pole examination;

          -  Previous intra-ocular surgery other than cataract surgery

          -  Hemodialysis, known bleeding disorders or use of anticoagulants drugs other than
             aspirin

          -  Prothrombin time, partial thromboplastin time or platelet count without normal limits

          -  History of previous thromboembolic events
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodrigo Jorge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of São Paulo</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2010</study_first_posted>
  <last_update_submitted>September 13, 2010</last_update_submitted>
  <last_update_submitted_qc>September 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>Retinal detachment</keyword>
  <keyword>Vitreous Hemorrhage</keyword>
  <keyword>Preoperative Ranibizumab</keyword>
  <keyword>pars plana vitrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Temazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

